Previous Article | Next Article 
Journal of Virology, May 1999, p. 3886-3892, Vol. 73, No. 5
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Intracellular Formation and Processing of the
Heterotrimeric gH-gL-gO (gCIII) Glycoprotein Envelope Complex of
Human Cytomegalovirus
Mary T.
Huber and
Teresa
Compton*
Program in Cellular and Molecular Biology and
Department of Medical Microbiology and Immunology, University of
Wisconsin, Madison, Wisconsin 53706
Received 7 December 1998/Accepted 1 February 1999
 |
ABSTRACT |
The human cytomegalovirus (HCMV) gCIII complex contains
glycoprotein H (gH; gpUL75), glycoprotein L
(gL; gpUL115), and glycoprotein O (gO; gpUL74). To examine
how gH, gL, and gO interact within HCMV-infected cells to assemble
the tripartite complex, pulse-chase experiments were performed. These
analyses demonstrated that gH and gL associate by the end of
the pulse period to form a disulfide dependent gH-gL complex.
Subsequently, the gH-gL complex interacts with a 100-kDa precursor form
of gO to form a 220-kDa precursor of the mature gH-gL-gO complex that
contains a 125-kDa form of gO. The 220-kDa precursor complex (pgCIII)
was sensitive to treatment with endoglycosidase H (endo H), while the
mature gCIII complex was essentially resistant to digestion with
this enzyme, suggesting that formation of pgCIII complex occurs in the
endoplasmic reticulum (ER) and is processed to mature gH-gL-gO (gCIII)
in a post-ER compartment. While the N-linked glycans on the 100-kDa
form of gO were modified to endo H-resistant states as the 125-kDa gO formed, additional posttranslational modifications were detected on gO.
These processing alterations were non-N-linked oligosaccharide modifications that could not be accounted for by phosphorylation or by
O-glycosylation of the type sensitive to O-glycanase.
Of gH, gL, gO, and the various complexes that they form, only the mature form of the complex was detectable at the infected cell membrane, as judged by surface biotinylation studies.
 |
INTRODUCTION |
Human cytomegalovirus (HCMV), the
largest of the human herpesviruses, has a glycoprotein
coding capacity unparalleled by other viruses. Laboratory strains, such
as AD169, contain at least 57 open reading frames (ORFs) with the
predictive features of glycoproteins, while clinical
isolates, such as Toledo, contain an additional 13 ORFs that may also
encode glycoproteins (5, 6). This tremendous
glycoprotein coding capacity implies a large array of
glycoproteins, some of which are likely functionally
redundant, while others are proposed to play specialized functional
roles tailored to replication and pathogenic features in the biology of
HCMV infection. It is noteworthy, therefore, that few
glycoprotein gene products have been characterized with
respect to biosynthesis within infected cells and incorporation into
the virion. To date, only one envelope glycoprotein,
glycoprotein B (gB; gpUL55), has been intensively
characterized at this level (reviewed in reference 3).
The gCIII complex is one of three high-molecular-mass,
disulfide-dependent glycoprotein complexes found in
the HCMV envelope (11). For many years, the only
known component of the 240-kDa gCIII complex was the
glycoprotein H (gH) homolog (8, 11, 26, 27).
Based on the proposed function of HCMV gH (19, 24,
26), this glycoprotein complex likely has an
indispensable role in viral fusion events. Subsequently, the HCMV
glycoprotein L (gL) homolog (UL115) (18, 29)
was also found to be a constituent of the gCIII complex (15,
21). Recently, a third viral gene product was confirmed to be a
member of the gCIII complex (15, 21). We have reported the
identification of this third component as the product of the HCMV UL74
ORF, which we designated glycoprotein O (gO)
(16). Thus, it is now known that the gCIII is a
heterotrimeric glycoprotein complex composed of the
products of three distinct HCMV genes, UL75 (gH), UL115 (gL), and UL74 (gO).
The purpose of this study was to characterize the biosynthesis of gO
and to define the sequence of events that leads to the formation of the
mature complex containing all three proteins. Pulse chase analysis
revealed a precursor-product relationship between a 100-kDa
endoglycosidase H (endo H)-sensitive form of gO and the diffusely
migrating, endo H-resistant 125-kDa form of gO. The 125-kDa gO, which
is the form found in mature gCIII, has additional posttranslational
modifications that could not be attributed to N-glycosylation or
phosphorylation, nor could they be identified as O-linked
glycosylation. Our study also revealed that the tripartite gH-gL-gO
complex assembles in two distinct steps. First, gH and gL associate via
disulfide bonding with very rapid kinetics to form a gH-gL complex.
Subsequently, the 100-kDa form of gO associates with gH-gL to form a
220-kDa high-mannose-decorated precursor gCIII (pgCIII) complex,
which is processed to the mature gCIII complex in a
post-endoplasmic reticulum (ER) compartment. Of the various
forms of gH, gL, gO, and their associated complexes, only the mature
gCIII complex was detectable at the plasma membrane of infected
cells. Together, these data form the basis for an understanding of the
pathway required for formation of the tripartite gH-gL-gO complex.
 |
MATERIALS AND METHODS |
Cells, viruses, and antibodies.
Human fibroblast (IF) cells
were cultured as previously described (7). The AD169 strain
of HCMV was grown and titered as previously described (7).
Monoclonal antibodies 14-4b, 27-78, and 7-17, generously supplied by W. Britt, and polyclonal antibody 26388, kindly provided by A. Minson,
were described previously (2, 4, 15). The generation of
antibody 6824 and of the anti-UL74 (gO) serum was also described
previously (7, 16).
Radiolabeling of infected cell proteins.
Steady-state
labeling of HCMV-infected IF cells was performed as previously
described (15). For 32P labeling, infected cells
were incubated for 16 h in medium containing 10% fetal bovine
serum and [32P]orthophosphate (500 mCi/ml; Amersham). For
pulse-chase labeling, IF cells were infected at a multiplicity of
infection of approximately 3. At 3 days postinfection, cells were
starved for 1 h in methionine-cysteine-deficient medium and then
pulse-labeled with 300 µCi of [35S]methionine-cysteine
(NEN) per ml for 20 min. Cell monolayers were rinsed with
phosphate-buffered saline (PBS) and chased in cell culture medium
supplemented with 10% fetal bovine serum and a 100-fold concentration
of cold methionine. At various time intervals, the cells were
harvested, lysed, and subjected to immunoprecipitation.
Immunoprecipitations.
Immunoprecipitations were performed as
previously described (15). For sequential
immunoprecipitations, the antibody-antigen complexes from the primary
immunoprecipitations were eluted from the protein A beads by incubation
in 2% sodium dodecyl sulfate (SDS)-50 mM dithiothreitol (DTT) at
95°C for 3 min. The eluted protein solutions were diluted up to 1 ml
with lysis buffer (for a final concentration of 0.2% SDS-2.5 mM DTT),
the second immunoprecipitating antibody was added, and the
immunoprecipitation proceeded as usual. Immunoprecipitates were
resolved by SDS-polyacrylamide gel electrophoresis (PAGE). The
resultant gels were dried and imaged with a GS-525 Molecular Imager
(Bio-Rad).
Enzymatic digestions.
For digestion with endo H (Boehringer
Mannheim), immunoprecipitated proteins were eluted from the protein A
beads in 0.5% SDS at 95°C for 3 min. An equal volume of 100 mM
sodium citrate (pH 5.5) was added to the eluted protein solution. Each
sample was divided into two aliquots, one receiving 10 mU of enzyme and the other receiving an equal volume of PBS. Digestion was allowed to
proceed for 16 h at 37°C. For digestion with
peptide:N-glycosidase F (PNGase; Boehringer Mannheim),
immunoprecipitated proteins were eluted from the protein A beads in a
solution of 0.45% SDS in PBS at 95°C for 3 min. The eluted protein
solution was diluted twofold with PBS and made 50 mM EDTA and 1%
Nonidet P-40. Each sample was split into two aliquots, one receiving 2 U of enzyme and the other receiving an equal volume of PBS. Digestion
was allowed to proceed for 16 h at 37°C. For digestion with
neuraminidase and O-glycosidase (Boehringer Mannheim),
immunoprecipitated proteins were eluted from the protein A beads in a
solution of 0.45% SDS in PBS (pH 6.3) at 95°C for 3 min. The eluted
protein solution was diluted twofold with PBS (pH 6.3) and made 1% in
Nonidet P-40. Each sample was split into two aliquots, one receiving 15 mU of neuraminidase and the other receiving an equal volume of PBS (pH 6.3). After a 4-h incubation at 37°C, 3 mU of
O-glycosidase or an equal volume of PBS (pH 6.3) was added
to the appropriate samples, and incubation proceeded for an additional
12 h.
Immunoblotting.
Immunoblotting was performed as previously
described (15). In brief, proteins were resolved by
SDS-PAGE (with and without reducing agents) and
electrotransferred to nitrocellulose (Millipore) for immunoblotting.
Primary antibodies were detected with horseradish peroxidase
(HRP)-conjugated goat anti-mouse or anti-rabbit antibodies (Pierce).
Streptavidin conjugated to HRP (SA-HRP; (Vector Laboratories) was used
for detection of biotinylated proteins. Renaissance Western blot
chemiluminesence reagent (NEN) was used to detect the HRP conjugates.
Cell surface biotinylation.
Biotinylation was performed
essentially as described previously (16). In brief, infected
cell monolayers were washed with PBS-MC (PBS supplemented with 1 mM
MgCl2 and 0.1 mM CaCl2) and chilled to 4°C.
EZ-link sulfo-NHS-LC biotin (Pierce) in PBS-MC (2 mg/ml) was added, and
the cells were incubated at 4°C for 1 h. The biotin solution was
removed, and cells were washed extensively with PBS-MC. To quench the
biotinylation reaction, 10 mM glycine in PBS-MC was added to the cells
for 10 min at 4°C. The glycine solution was removed, and the
cells were washed extensively with PBS-MC.
 |
RESULTS |
Kinetics of intracellular association of gH, gL, and gO.
To
characterize the biosynthesis of gO in comparison to one of its complex
partners, gH, pulse-chase labeling experiments were performed.
HCMV-infected cell proteins were immunoprecipitated by anti-gO or
anti-gH antibodies and analyzed by reducing SDS-PAGE (Fig.
1). In immunoprecipitations with the
anti-gO antibody (Fig. 1A), a 100-kDa protein was recovered in the
pulse sample (0 h of chase). Concurrent with the decrease in abundance
of the 100-kDa protein at later chase times was the appearance of a
diffusely migrating 125-kDa species. The migration pattern of this
125-kDa protein was similar to that of the 125-kDa gO found in the
gCIII complex (15, 16, 21). Immunoblotting of the
immunoprecipitated 125- and 100-kDa species revealed that both of these
proteins were reactive with the anti-gO antibody, confirming their
identities as forms of gO (data not shown). Given the order of
appearance of these two forms, it is likely that the 100-kDa gO is a
precursor of the 125-kDa gO. The processing of the 100-kDa gO to the
125-kDa gO was relatively slow, requiring nearly 6 h of chase. In
addition to these two forms of gO, two other coprecipitating proteins
of approximately 86 and 34 kDa were detected beginning at 1 to 2 h
of chase. The electrophoretic mobilities of these coprecipitating species suggested they represent gH and gL, respectively.

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 1.
Pulse-chase analysis of HCMV-infected cells (reducing
SDS-PAGE). HCMV-infected cells were pulse-labeled and chased for
various intervals up to 6 h. Cell lysates were immunoprecipitated
and subjected to reducing SDS-PAGE. (A) Immunoprecipitations with the
anti-gO antibody; (B) immunoprecipitations with the anti-gH antibody
14-4b. IP ab, immunoprecipitating antibody.
|
|
Pulse-chase analysis using an anti-gH antibody revealed a similar
pattern of immunoprecipitated proteins (Fig.
1B). At 0 h
of chase,
gH (86 kDa) was readily apparent. An approximately 34-kDa
protein,
likely representing gL, was also coprecipitated with
gH during the
pulse period. At approximately 1 h of chase, a faint
100-kDa
protein migrating directly above gH was seen; by 2 to
3 h of
chase, a 125-kDa coprecipitating protein reminiscent of
the 100- and
125-kDa forms of gO seen in Fig.
1A was
evident.
Confirmation of the identities of the coprecipitating
proteins.
Both the anti-gO and anti-gH antibodies coprecipitated a
number of proteins. The mobilities of most of the coimmunoprecipitating proteins were suggestive, but not definitive proof, of their
identities. To verify the identities of the coimmunoprecipitating
species, pulse-chase samples were first immunoprecipitated with anti-gO or anti-gH antibodies; proteins recovered in the precipitate were released and reimmunoprecipitated with anti-gH, -gL, or -gO antibodies. As shown in Fig. 2A, the 86- and 34-kDa
proteins that coprecipitated with the 100-kDa form of gO by 1 h of
chase were gH and gL, respectively. When the anti-gH antibody was used
as the initial precipitating antibody (Fig. 2B), the 34-kDa
coprecipitating protein was verified as gL, confirming the conclusion
that these two proteins associate with very rapid kinetics. In
addition, the 100- and 125-kDa proteins detected in the anti-gH
immunoprecipitates were confirmed as the 100- and 125-kDa forms of gO
(Fig. 2B).

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 2.
Sequential immunoprecipitations of the pulse-chase
samples. HCMV-infected cells were pulse-labeled and chased for various
intervals up to 3 h. Cell lysates were immunoprecipitated first
with either anti-gO or anti-gH antibodies (1st IP ab). The
immunoprecipitated proteins were eluted from the protein A beads by
incubation in 2% SDS-50 mM DTT at 95°C, diluted in
radioimmunoprecipitation assay buffer, and subjected to secondary
immunoprecipitation with anti-gH antibody 6824, anti-gL antibody 26388, or the anti-gO antibody (2nd IP ab). (A) Proteins
immunoprecipitated with the anti-gO antibody, which were
reimmunoprecipitated by anti-gH or anti-gL antibodies. (B) Proteins
immunoprecipitated with the anti-gH antibody 14-4b, which were
reimmunoprecipitated by anti-gO or anti-gL antibodies.
|
|
Besides the gH, gL, and gO proteins identified in the pulse-chase
analyses, other coprecipitating proteins of unknown identity
were
observed (Fig.
1 and
2). A closely migrating series of four
bands
between 56 and 66 kDa was detected at later chase times
in both anti-gO
and anti-gH immunoprecipitations (Fig.
1 and
2).
An antibody specific
for the HCMV pp65 tegument protein was reactive
with the
slowest-migrating (ca. 66-kDa) protein but with none
of the other
faster-migrating proteins (data not shown). Also,
in anti-gO
immunoprecipitations, a coprecipitating protein of
approximately 34 kDa
was prominent at early chase times and chased
into a more diffusely
migrating form of ca. 36 kDa, suggestive
of a glycosylated protein
(Fig.
1A and
2A). Based on the mobility
and the possible glycosylated
nature of this protein, it was originally
hypothesized that it
represented gL; however, the gL antibody
was not reactive with these
34- to 36-kDa proteins (Fig.
2A).
Efforts are now under way to
characterize these unidentified coprecipitating
proteins.
Kinetics of formation of disulfide-dependent complexes.
The reduced pulse-chase immunoprecipitations demonstrated the
very rapid association of gH and gL (at 0 h of chase), whereas the
three proteins (100-kDa gO, gH, and gL) were not coprecipitated until
ca. 1 h postsynthesis. To examine the corresponding
disulfide-dependent complexes that formed as a result of these various
interactions between gH, gL, and gO, immunoprecipitates of the
pulse-chase samples were analyzed under nonreducing conditions (Fig.
3). In the anti-gO immunoprecipitates,
the 100-kDa gO was evident at 0 h of chase (Fig. 3A). Between 0.5 and 1 h of chase, a species migrating slightly above the 220-kDa
protein standard was seen. This species (labeled as 220 kDa in the
figures) reached maximum levels by 2 h of chase and subsequently
waned over the course of the chase. By 1.5 to 2 h of chase, a
species migrating slower than the 220-kDa species was evident. This
species was previously demonstrated to be the mature gCIII complex,
known to contain gH, gL, and 125-kDa gO (15, 16). Consistent
with this finding was the appearance of the 125-kDa form of gO at chase
times when the mature gCIII complex was observed (compare Fig. 1 and
3). Of interest is the fact that at no time is free,
non-disulfide-bonded 125-kDa gO observed, suggesting it is
exclusively contained in the gCIII complex. This is in contrast to gH.
Figure 3B shows that gH and a 115-kDa gH-gL dimer (15) were
evident in the pulse sample. While the signal strength of these species
waned at later chase times, they did not decrease appreciably or to the
same degree as for gO. The 220-kDa species was recovered in anti-gH precipitates as well, followed by the appearance of mature gCIII complex at ca. 2 h of chase.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 3.
Pulse-chase analysis of HCMV-infected cells (nonreducing
SDS-PAGE). HCMV-infected cells were pulse-labeled and chased for
various intervals up to 6 h. Cell lysates were immunoprecipitated
and subjected to nonreducing SDS-PAGE. (A) Immunoprecipitations with
the anti-gO antibody; (B) Immunoprecipitations with the anti-gH
antibody 14-4b. IP ab, immunoprecipitating antibody.
|
|
The 220-kDa species is composed of gH, gL, and the 100-kDa form of
gO.
The unidentified 220-kDa species appeared at chase times when
gH, gL, and the 100-kDa gO were known to interact (Fig. 1 and 2),
suggesting that the 220-kDa species may represent a disulfide-linked complex of these three glycoproteins. Two approaches were
used to determine the composition of the 220-kDa species. First,
unreduced lysates of HCMV-infected cells were immunoblotted with
anti-gH, anti-gL, or anti-gO antibodies (Fig.
4A). Similar to the mature gCIII complex,
the 220-kDa species was reactive with antibodies to all three
glycoproteins, demonstrating the presence of gH, gL, and
some form of gO. We also performed excision/reduction experiments. For
this analysis, the immunoprecipitated 220-kDa species was excised from
a nonreducing SDS-polyacrylamide gel, reduced, and subjected to a
second SDS-PAGE to resolve the separated components of this complex
(Fig. 4B). This analysis revealed that the 220-kDa gCIII contained the
100-kDa form of gO, in contrast to the mature gCIII, which contained
the 125-kDa form of gO.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 4.
Analysis of the composition of the 220-kDa species. (A)
HCMV-infected cell lysates were subjected to nonreducing SDS-PAGE,
electroblotted to nitrocellulose, and probed with anti-gH antibody
6824, anti-gL antibody 26388, or the anti-gO antibody. IB ab,
immunoblotting antibody. (B) Excision/reduction analysis of mature
gCIII and the 220-kDa species. 35S-labeled HCMV-infected
cell lysates were immunoprecipitated with either the anti-gO antibody
( -O) or the anti-gH antibody 14-4b ( -H) and subjected to
nonreducing SDS-PAGE. The upper panel shows the resultant autoradiogram
of these immunoprecipitations (positions of gCIII and the 220-kDa
species are indicated at the sides). gCIII and the 220-kDa species were
excised from products of both immunoprecipitations and subjected to
reducing SDS-PAGE. The identities of the resolved proteins are marked
between the two lower panels.
|
|
Endo H sensitivity of gH, gL, gO, and their associated
complexes.
The pulse-chase analyses suggest a stepwise association
of gCIII. First, gH and gL associate, followed by their interaction with a 100-kDa form of gO to form the 220-kDa pgCIII complex. Subsequently, the mature form of the gCIII complex, containing gH, gL,
and the 125-kDa gO, is evident. The rapid initial association of gH and
gL argues that the formation of gH-gL complex occurs in the ER, but the
subcellular site where the pgCIII or mature gCIII complex forms is
unclear. To investigate whether the pgCIII and/or mature gCIII complex
forms in the ER, immunoprecipitate of pulse-chase samples with the
anti-gO antibody were digested with endo H, which cleaves high-mannose
N-linked glycans from the polypeptide backbone. Sensitivity to endo H
is indicative of ER localization, while endo H resistance is evidence
of glycoproteins whose N-linked glycans were processed to a
complex form in the Golgi complex. Figure
5A shows the digested immunoprecipitated proteins analyzed by reducing SDS-PAGE. The 100-kDa form of gO shifts
in electrophoretic mobility to an approximately 54-kDa species in the
presence of endo H that correlates well with the predicted polypeptide
backbone mass of gO (16). The mobility of the 125-kDa form
of gO, seen at later chase times, was only slightly affected by endo H,
suggesting that it contained primarily complex-type glycans. These data
suggest that the 100-kDa form of gO is a high-mannose precursor of the
processed 125-kDa gO. Similarly, the coprecipitating gH, evident by
1 h of chase, was also shifted upon endo H treatment to an
approximately 78-kDa species, correlating well with the predicted
peptide backbone mass of gH. An endo H-resistant form of gH was
apparent at 3 to 4 h of chase. The digestion pattern of gL
could not be accurately assessed due to the low level of incorporation
of radioactive label and the presence of the unidentified 30- to
35-kDa coprecipitating species. We conducted the same
experiment but analyzed the samples under nonreducing conditions (Fig.
5B). The pgCIII complex shifted in mobility upon endo H digestion,
demonstrating the presence of high-mannose oligosaccharides and
consistent with our finding that the 100-kDa gO is contained in this
species. In contrast, the mature form of the complex was largely
unaffected by treatment with endo H. This observation is in agreement
with the results of Li et al., who demonstrated that endo H
treatment of virion-derived gCIII caused only a slight increase
in SDS-PAGE mobility (21). These results suggest that
gH, gL, and the 100-kDa gO (pgO in Fig. 5) associate to form a 220-kDa
pgCIII complex in the ER. The pgCIII complex is processed in the Golgi
apparatus to yield the mature form of the gCIII complex, consisting of
gH, gL, and the 125-kDa gO, which contain complex N-linked
glycans.

View larger version (75K):
[in this window]
[in a new window]
|
FIG. 5.
Endo H digestion of pulse-chase samples. HCMV-infected
cells were pulse-labeled and chased for various intervals up to
4 h. Cell lysates were immunoprecipitated with the anti-gO
antibody, and the immunoprecipitated proteins were incubated
in the presence or absence of endo H as outlined in Materials and
Methods. and + denote positions of the proteins after no
treatment and after treatment with endo H, respectively. The digested
proteins were resolved by SDS-PAGE under reducing (A) and nonreducing
(B) conditions. pgO, precursor gO.
|
|
Posttranslational modification of the 125-kDa gO.
To further
characterize the posttranslational modifications associated with
gCIII, proteins from anti-gO immunoprecipitations of pulse-chase
samples were digested with PNGase to remove all N-linked
oligosaccharides. If gO contained exclusively N-linked oligosaccharides, PNGase digestion would be expected to shift the
125-kDa gO to a 54-kDa form (Fig. 6A).
As expected, this treatment shifted the mobility of the
100-kDa pgO to 54 kDa. In contrast, the 125-kDa gO did not shift to the
54-kDa polypeptide backbone species but rather shifted to a diffusely
migrating species of approximately 60 to 65 kDa. This finding suggests
that 125-kDa gO has a non-N-linked oligosaccharide modification
accounting for ca. 5 to 10 kDa of mass. The diffuse migration pattern
of the 60- to 65-kDa species suggested glycosylation such as O-linked glycans. Analysis of the gO amino acid sequence by the NetOGlyc 2.0 prediction program (12-14) indicated a strong predilection for O-glycosylation of this glycoprotein. To test for
the presence of O-linked glycans and sialic acid on the 125-kDa gO,
anti-gO immunoprecipitates were digested with neuraminidase,
neuraminidase followed by O-glycosidase, or a
combination of neuraminidase, O-glycosidase,
and PNGase. The mobility of the 125-kDa gO was slightly altered by
neuraminidase alone but not significantly affected by digestion with
O-glycosidase (Fig. 6B). However, it should be noted that
the specificity of O-glycosidase is limited to cleaving only
the disaccharide unit Gal-
(1-3)-GalNAc from O-linked
oligosaccharides (9) and thus may not cleave the types of
O-linked glycans that might be present on gO. To test whether a
phosphorylation event could account for this non-N-linked modification on the 125-kDa gO, HCMV-infected cells were metabolically labeled with [32P]orthophosphate. Immunoprecipitations
of these cell lysates did not reveal the phosphorylation of either the
220-kDa pgCIII or mature gCIII complex, although gB, which is
known to be phosphorylated (10, 25), did incorporate the
32P label (Fig. 6C).

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 6.
(A) PNGase digestion of pulse-chase samples.
HCMV-infected cells were pulse-labeled and chased for various intervals
up to 4 h. Cell lysates were immunoprecipitated with the anti-gO
antibody, and the immunoprecipitated proteins were incubated
in the presence or absence of PNGase as outlined in Materials and
Methods. and + denote positions of the proteins after no
treatment and after treatment with PNGase, respectively. The digested
proteins were resolved by reducing SDS-PAGE. (B)
O-glycosidase and neuraminidase digestion of the 125-kDa gO.
35S-labeled HCMV-infected lysates were
immunoprecipitated by the anti-gO antibody, and the
immunoprecipitated proteins were digested with neuraminidase (NA),
neuraminidase followed by O-glycosidase (NA/O-glyc.),
neuraminidase followed by O-glycosidase and PNGase
(NA/O-glyc./PNGase), or PNGase alone (PNGase) or were untreated.
The digested proteins were resolved by reducing SDS-PAGE. (C)
Immunoprecipitations of [32P]orthophosphate-labeled
HCMV lysates. Mock infected (M) and HCMV-infected (I) cells were
metabolically labeled with either [32P]orthophosphate or
[35S]methionine-cysteine. Lysates of these labeled cells
were immunoprecipitated with either the anti-gO antibody or a cocktail
of anti-gB antibodies 7-17 and 27-78. Immunoprecipitated proteins were
resolved by nonreducing SDS-PAGE.
|
|
The gCIII complex is the predominant form of gH, gL, or gO at the
cell surface.
To determine which forms of gH, gL, gO, and their
associated complexes were found at the plasma membrane of HCMV-infected cells, cell surface proteins were biotinylated and
immunoprecipitated with anti-gO or anti-gH antibodies.
Immunoprecipitated proteins were resolved by nonreducing SDS-PAGE, and
the biotinylated species were detected with SA-HRP. Figure
7 shows that the gCIII complex was the
major biotinylated species in immunoprecipitations with either anti-gO
or anti-gH antibodies. In contrast, neither the gH-gL complex nor
the pgCIII complex appeared to be biotinylated, suggesting that they
were not present at the plasma membrane of infected cells.

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 7.
Cell surface biotinylation of HCMV-infected cells.
Mock-infected (M) and HCMV-infected (I) cells were surface biotinylated
(described in Materials and Methods), lysed, and immunoprecipitated
with either the anti-gO antibody or anti-gH antibody 14-4b. The
immunoprecipitated proteins were resolved by nonreducing SDS-PAGE,
electroblotted, and probed with SA-HRP. As controls, anti-gO and
anti-gH immunoprecipitations of 35S-labeled HCMV-infected
lysates were also resolved by nonreducing SDS-PAGE and imaged.
|
|
 |
DISCUSSION |
The HCMV gCIII is a multicomponent envelope
glycoprotein complex that contains the HCMV gH and gL
homologs as well as the product of the UL74 gene, gO. The function of
the gCIII complex in the viral life cycle is not well defined.
Functional studies of HCMV gH and other herpesvirus gH homologs have
implicated this glycoprotein in the direct fusion events
that occur during entry and cell-to-cell spread of virus, although the
specific molecular role of gH is not clear. In the case of HCMV gH, its
role in fusion may be facilitated by engagement of a cellular receptor
(19, 20). However, this cellular protein has not been
genetically characterized. Studies of the gL homologs have clearly
demonstrated a chaperone-type function that is generally required for
the proper processing and targeting of its partner, gH (8, 17, 18, 22, 28, 29, 31). Whether gL has any additional function(s) is not
known. As for HCMV gO and its homologs in other betaherpesviruses, it
is possible only to speculate on potential functions in the absence of
any direct evidence. As a prerequisite to functional studies of
the tripartite complex and its components, it is crucial to have a
thorough knowledge of the intracellular processing pathway that
these three proteins undergo to produce mature functional complex.
Heterotrimeric viral glycoprotein complexes composed of
three distinct gene products are exceedingly rare. To date, only one other tripartite viral glycoprotein complex, the
Epstein-Barr virus gH-gL-gp42 complex, has been described
(23). In this study, we have examined the intracellular
formation and processing of a tripartite viral glycoprotein
complex. The results obtained have yielded a model for the biosynthesis
of the tripartite gH-gL-gO complex (Fig.
8). Shortly after or coincident with
their translation in the ER, gH and gL quickly associate to form a
115-kDa disulfide-dependent gH-gL dimer. Within 60 min of gH-gL
formation, a precursor form of gO associates with gH-gL to form the
220-kDa pgCIII complex. Based on the presence of high-mannose N-linked
oligosaccharides on pgIII, the formation of the tripartite precursor
likely occurs in the ER. By 1.5 to 2 h of chase, mature gH-gL-gO
complex becomes apparent, which corroborates earlier time course
studies of this complex (1, 21). The subsequent processing
of precursor to the mature form of the complex likely occurs in post-ER
compartments since the mature form contains mainly
complex-type glycans and a 125-kDa form of gO. Our
analysis revealed that 125-kDa gO contains additional non-N-linked
modifications that we were unable to identify. The presence of O-linked
glycosylation on gO is still a possibility, considering the limited
type of sugar moieties recognized and cleaved by
O-glycosidase (9). Also, other, less common
posttranslational modifications, such as sulfation, may be present on
the 125-kDa gO. Further analysis of the 125-kDa gO will be required to
address this matter. Once these post-ER processing steps have been
completed, the mature gH-gL-gO complex is competent to traffic to
the plasma membrane. It should be noted that this model
assumes a stoichiometric ratio of 1:1:1 for the
glycoproteins constituting the gCIII complex, although such
a ratio remains to be formally demonstrated, as does the precise
molecular mass of the complex.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 8.
Model of the intracellular formation and processing of
the tripartite gH-gL-gO HCMV envelope complex. For detailed description
of the model, see the text.
|
|
Although this model provides a basic framework for understanding
the intracellular processing of the gH-containing complex, more
detailed analyses will be required to answer additional questions concerning the associations of gH, gL, and gO. Specifically, it is not
known how interdependent gH, gL, and gO are for their processing and
targeting. It has been well documented that gH requires association with gL for proper processing of gH's N-linked glycans and for targeting of the resulting gH-gL complex to the plasma membrane (17, 18, 22, 24, 28, 29, 31). Coexpression of gH and gL in
the absence of other HCMV gene products has been demonstrated to be
sufficient for transport of gH-gL complex to the cell surface, implying
that gH and gL do not require any additional viral gene products for
targeting to the plasma membrane (18, 24, 29). Our analyses
also revealed the formation of a gH-gL complex in HCMV-infected cells,
but interestingly, this gH-gL complex was not detectable at the cell
surface. This finding suggests that the gH-gL complex is unable to
reach the cell surface without coexpression of gO in HCMV-infected
cells. Currently, our laboratory is generating a gO-deficient HCMV
strain to address the intricate nature of the gH, gL, and gO
interactions. Likewise, it is not known whether proper processing of gO
requires gH and/or gL. Also, gO may be dependent on association with gH
for its membrane localization, as preliminary evidence suggests that gO
may be a soluble, rather than membrane-spanning, protein (data not
shown). An in-depth characterization of gO is now under way.
Another intriguing issue involves the form(s) of the gH-containing
complex(es) in the virion. Li et al. have reported that in addition to
the three-protein complex, free uncomplexed forms of gH exist in the
viral envelope (21). Although our study did not investigate
virion-associated forms of gH, gL, and gO, we did demonstrate that
mature form of the complex was the predominant form of gH at the cell
surface, while no uncomplexed forms of gH were detectable. Our findings
do not necessarily rule out the possibility that uncomplexed forms of
gH are present in other subcellular membranes, in particular those that
may serve as sites of envelopment for HCMV. In fact, our pulse-chase
analyses did demonstrate the persistence of free gH and gH-gL dimer
throughout a 6-h chase. It is interesting that recent studies of
the Epstein-Barr virus gH-gL-gp42 complex have suggested that the viral
envelope contains both bipartite gH-gL complexes and tripartite
gH-gL-gp42 complexes (30). Additional in-depth
investigation of gH, gL, gO, and their intracellular and
virion-associated complexes will be required for a complete
understanding of their ramifications with respect to the biology of HCMV.
 |
ACKNOWLEDGMENT |
This study was supported in part by Public Health Service grant
AI-34998.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Medical Microbiology and Immunology, University of Wisconsin, Madison, WI 53706. Phone: (608) 262-1474. Fax: (608) 262-8418. E-mail: tcompton{at}facstaff.wisc.edu.
 |
REFERENCES |
| 1.
|
Bogner, E.,
M. Reschke,
B. Reis,
W. Britt, and K. Radsak.
1992.
Recognition of compartmentalized intracellular analogs of glycoprotein H of human cytomegalovirus.
Arch. Virol.
126:67-80[Medline].
|
| 2.
|
Britt, W. J.
1984.
Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus.
Virology
135:369-378[Medline].
|
| 3.
|
Britt, W. J., and M. Mach.
1996.
Human cytomegalovirus glycoproteins.
Intervirology
39:401-412[Medline].
|
| 4.
|
Britt, W. J.,
L. Vulger,
E. J. Butfiloski, and E. B. Stephens.
1990.
Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response.
J. Virol.
64:1079-1085[Abstract/Free Full Text].
|
| 5.
|
Cha, T.-A.,
E. Tom,
G. W. Kemble,
G. M. Duke,
E. S. Mocarski, and R. R. Spaete.
1996.
Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains.
J. Virol.
70:78-83[Abstract/Free Full Text].
|
| 6.
|
Chee, M. S.,
A. T. Bankier,
S. Beck,
R. Bohni,
C. M. Brown,
R. Cerny,
T. Horsnell,
C. A. Hutchison III,
T. Kouzarides,
J. A. Martignetti,
E. Preddie,
S. C. Satchwell,
P. Tomlinson,
K. M. Weston, and B. G. Barrell.
1990.
Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169.
Curr. Top. Microbiol. Immunol.
154:125-169[Medline].
|
| 7.
|
Compton, T.
1993.
An immortalized human fibroblast cell line is permissive for human cytomegalovirus infection.
J. Virol.
67:3644-3648[Abstract/Free Full Text].
|
| 8.
|
Cranage, M. P.,
G. L. Smith,
S. E. Bell,
H. Hart,
C. Brown,
A. T. Bankier,
P. Tomlinson,
B. G. Barrell, and T. C. Minson.
1988.
Identification and expression of a human cytomegalovirus glycoprotein with homology to the Epstein-Barr virus BXLF2 product, varicella-zoster virus gpIII, and herpes simplex virus type 1 glycoprotein H.
J. Virol.
62:1416-1422[Abstract/Free Full Text].
|
| 9.
|
Endo, Y., and A. Kobata.
1976.
Partial purification and characterization of an endo-alpha-N-acetylgalactosaminidase from the culture of medium of Diplococcus pneumoniae.
J. Biochem. (Tokyo)
80:1-8[Abstract/Free Full Text].
|
| 10.
|
Fish, K. N.,
C. Soderberg-Naucler, and J. A. Nelson.
1998.
Steady-state plasma membrane expression of human cytomegalovirus gB is determined by the phosphorylation state of Ser900.
J. Virol.
72:6657-6664[Abstract/Free Full Text].
|
| 11.
|
Gretch, D. R.,
B. Kari,
L. Rasmussen,
R. C. Gehrz, and M. F. Stinski.
1988.
Identification and characterization of three distinct families of glycoprotein complexes in the envelopes of human cytomegalovirus.
J. Virol.
62:875-881[Abstract/Free Full Text].
|
| 12.
|
Hansen, J. E.,
O. Lund,
J. Engelbrecht,
H. Bohr, and J. O. Nielsen.
1995.
Prediction of O-glycosylation of mammalian proteins: specificity patterns of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase.
Biochem. J.
308(Pt. 3):801-813.
|
| 13.
|
Hansen, J. E.,
O. Lund,
J. O. Nielsen, and S. Brunak.
1996.
O-GLYCBASE: a revised database of O-glycosylated proteins.
Nucleic Acids Res.
24:248-252[Abstract/Free Full Text].
|
| 14.
|
Hansen, J. E.,
O. Lund,
N. Tolstrup,
A. A. Gooley,
K. L. Williams, and S. Brunak.
1998.
NetOglyc: prediction of mucin type O-glycosylation sites based on sequence context and surface accessibility.
Glycoconi. J.
15:115-130.
|
| 15.
|
Huber, M. T., and T. Compton.
1997.
Characterization of a novel third member of the human cytomegalovirus glycoprotein H-glycoprotein L complex.
J. Virol.
71:5391-5398[Abstract/Free Full Text].
|
| 16.
|
Huber, M. T., and T. Compton.
1998.
The human cytomegalovirus UL74 gene encodes the third component of the glycoproteinH-glycoprotein L-containing envelope complex.
J. Virol.
72:8191-8197[Abstract/Free Full Text].
|
| 17.
|
Hutchinson, L.,
H. Browne,
V. Wargent,
N. Davis-Poynter,
S. Primorac,
K. Goldsmith,
A. C. Minson, and D. C. Johnson.
1992.
A novel herpes simplex virus glycoprotein, gL, forms a complex with glycoprotein H (gH) and affects normal folding and surface expression of gH.
J. Virol.
66:2240-2250[Abstract/Free Full Text].
|
| 18.
|
Kaye, J. F.,
U. A. Gompels, and A. C. Minson.
1992.
Glycoprotein H of human cytomegalovirus (HCMV) forms a stable complex with the HCMV UL115 gene product.
J. Gen. Virol.
73:2693-2698[Abstract/Free Full Text].
|
| 19.
|
Keay, S., and B. Baldwin.
1991.
Anti-idiotype antibodies that mimic gp86 of human cytomegalovirus inhibit viral fusion but not attachment.
J. Virol.
65:5124-5728[Abstract/Free Full Text].
|
| 20.
|
Keay, S.,
T. C. Merigan, and L. Rasmussen.
1989.
Identification of cell surface receptors for the 86-kilodalton glycoprotein of human cytomegalovirus.
Proc. Natl. Acad. Sci. USA
86:10100-10103[Abstract/Free Full Text].
|
| 21.
|
Li, L.,
J. A. Nelson, and W. J. Britt.
1997.
Glycoprotein H-related complexes of human cytomegalovirus: identification of a third protein in the gCIII complex.
J. Virol.
71:3090-3097[Abstract/Free Full Text].
|
| 22.
|
Li, Q.,
C. Buranathai,
C. Gross, and L. M. Hutt-Fletcher.
1997.
Chaperone functions common to nonhomologous EBV gl and VSV gL proteins.
J. Virol.
71:1667-1670[Abstract/Free Full Text].
|
| 23.
|
Li, Q.,
S. M. Turk, and L. M. Hutt-Fletcher.
1995.
The Epstein-Barr virus (EBV) BZLF2 gene product associates with the gH and gL homologs of EBV and carries an epitope critical to infection of B cells but not of epithelial cells.
J. Virol.
69:3987-3994[Abstract/Free Full Text].
|
| 24.
|
Milne, R. S.,
D. A. Paterson, and J. C. Booth.
1998.
Human cytomegalovirus glycoprotein H/glycoprotein L complex modulates fusion-from-without.
J. Gen. Virol.
79(Pt.4):855-865[Abstract].
|
| 25.
|
Norais, N.,
J. A. Hall,
L. Gross,
D. Tang,
S. Kaur,
S. H. Chamberlain,
R. L. Burke, and F. Marcus.
1996.
Evidence for a phosphorylation site in cytomegalovirus glycoprotein gB.
J. Virol.
70:5716-5719[Abstract/Free Full Text].
|
| 26.
|
Pachl, C.,
W. S. Probert,
K. M. Hermsen,
F. R. Masiarz,
L. Rasmussen,
T. C. Merigan, and R. R. Spaete.
1989.
The human cytomegalovirus strain Towne glycoprotein H gene encodes glycoprotein p86.
Virology
169:418-426[Medline].
|
| 27.
|
Rasmussen, L.,
R. Nelson,
D. Kelsall, and T. Merigan.
1984.
Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus.
Proc. Natl. Acad. Sci. USA
81:876-880[Abstract/Free Full Text].
|
| 28.
|
Roop, C.,
L. Hutchinson, and D. C. Johnson.
1993.
A mutant herpes simplex virus type 1 unable to express glycoprotein L cannot enter cells, and its particles lack glycoprotein H.
J. Virol.
67:2285-2297[Abstract/Free Full Text].
|
| 29.
|
Spaete, R. R.,
K. Perot,
P. I. Scott,
J. A. Nelson,
M. F. Stinski, and C. Pachl.
1993.
Coexpression of truncated human cytomegalovirus gH with the UL115 gene product or the truncated human fibroblast growth factor receptor results in the transport of gH to the cell surface.
Virology
193:853-861[Medline].
|
| 30.
|
Wang, X.,
W. J. Kenyon,
Q. Li,
J. Mullberg, and L. M. Hutt-Fletcher.
1998.
Epstein-Barr virus uses different complexes of glycoproteins gH and gL to infect B lymphocytes and epithelial cells.
J. Virol.
72:5552-5558[Abstract/Free Full Text].
|
| 31.
|
Yaswen, L. R.,
E. B. Stephens,
L. C. Davenport, and L. M. Hutt-Fletcher.
1993.
Epstein-Barr glycoprotein gp85 associates with the BKRF2 gene product and is incompletely processed as a recombinant protein.
Virology
195:387-396[Medline].
|
Journal of Virology, May 1999, p. 3886-3892, Vol. 73, No. 5
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Ryckman, B. J., Chase, M. C., Johnson, D. C.
(2010). Human Cytomegalovirus TR Strain Glycoprotein O Acts as a Chaperone Promoting gH/gL Incorporation into Virions but Is Not Present in Virions. J. Virol.
84: 2597-2609
[Abstract]
[Full Text]
-
Wille, P. T., Knoche, A. J., Nelson, J. A., Jarvis, M. A., Johnson, D. C.
(2010). A Human Cytomegalovirus gO-Null Mutant Fails To Incorporate gH/gL into the Virion Envelope and Is Unable To Enter Fibroblasts and Epithelial and Endothelial Cells. J. Virol.
84: 2585-2596
[Abstract]
[Full Text]
-
Ryckman, B. J., Rainish, B. L., Chase, M. C., Borton, J. A., Nelson, J. A., Jarvis, M. A., Johnson, D. C.
(2008). Characterization of the Human Cytomegalovirus gH/gL/UL128-131 Complex That Mediates Entry into Epithelial and Endothelial Cells. J. Virol.
82: 60-70
[Abstract]
[Full Text]
-
English, E. P., Chumanov, R. S., Gellman, S. H., Compton, T.
(2006). Rational Development of beta-Peptide Inhibitors of Human Cytomegalovirus Entry. J. Biol. Chem.
281: 2661-2667
[Abstract]
[Full Text]
-
Wang, D., Shenk, T.
(2005). Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc. Natl. Acad. Sci. USA
102: 18153-18158
[Abstract]
[Full Text]
-
Kinzler, E. R., Compton, T.
(2005). Characterization of Human Cytomegalovirus Glycoprotein-Induced Cell-Cell Fusion. J. Virol.
79: 7827-7837
[Abstract]
[Full Text]
-
Varnum, S. M., Streblow, D. N., Monroe, M. E., Smith, P., Auberry, K. J., Pasa-Tolic, L., Wang, D., Camp, D. G. II, Rodland, K., Wiley, S., Britt, W., Shenk, T., Smith, R. D., Nelson, J. A.
(2004). Identification of Proteins in Human Cytomegalovirus (HCMV) Particles: the HCMV Proteome. J. Virol.
78: 10960-10966
[Abstract]
[Full Text]
-
Kattenhorn, L. M., Mills, R., Wagner, M., Lomsadze, A., Makeev, V., Borodovsky, M., Ploegh, H. L., Kessler, B. M.
(2004). Identification of Proteins Associated with Murine Cytomegalovirus Virions. J. Virol.
78: 11187-11197
[Abstract]
[Full Text]
-
Akkapaiboon, P., Mori, Y., Sadaoka, T., Yonemoto, S., Yamanishi, K.
(2004). Intracellular Processing of Human Herpesvirus 6 Glycoproteins Q1 and Q2 into Tetrameric Complexes Expressed on the Viral Envelope. J. Virol.
78: 7969-7983
[Abstract]
[Full Text]
-
Mori, Y., Akkapaiboon, P., Yonemoto, S., Koike, M., Takemoto, M., Sadaoka, T., Sasamoto, Y., Konishi, S., Uchiyama, Y., Yamanishi, K.
(2004). Discovery of a Second Form of Tripartite Complex Containing gH-gL of Human Herpesvirus 6 and Observations on CD46. J. Virol.
78: 4609-4616
[Abstract]
[Full Text]
-
Mori, Y., Akkapaiboon, P., Yang, X., Yamanishi, K.
(2003). The Human Herpesvirus 6 U100 Gene Product Is the Third Component of the gH-gL Glycoprotein Complex on the Viral Envelope. J. Virol.
77: 2452-2458
[Abstract]
[Full Text]
-
Rasmussen, L., Geissler, A., Cowan, C., Chase, A., Winters, M.
(2002). The Genes Encoding the gCIII Complex of Human Cytomegalovirus Exist in Highly Diverse Combinations in Clinical Isolates. J. Virol.
76: 10841-10848
[Abstract]
[Full Text]
-
Theiler, R. N., Compton, T.
(2002). Distinct Glycoprotein O Complexes Arise in a Post-Golgi Compartment of Cytomegalovirus-Infected Cells. J. Virol.
76: 2890-2898
[Abstract]
[Full Text]
-
Theiler, R. N., Compton, T.
(2001). Characterization of the Signal Peptide Processing and Membrane Association of Human Cytomegalovirus Glycoprotein O. J. Biol. Chem.
276: 39226-39231
[Abstract]
[Full Text]
-
Bahr, U., Darai, G.
(2001). Analysis and Characterization of the Complete Genome of Tupaia (Tree Shrew) Herpesvirus. J. Virol.
75: 4854-4870
[Abstract]
[Full Text]
-
Mach, M., Kropff, B., Dal Monte, P., Britt, W.
(2000). Complex Formation by Human Cytomegalovirus Glycoproteins M (gpUL100) and N (gpUL73). J. Virol.
74: 11881-11892
[Abstract]
[Full Text]
-
Wang, S.-K., Duh, C.-Y., Chang, T.-T.
(2000). Cloning and identification of regulatory gene UL76 of human cytomegalovirus. J. Gen. Virol.
81: 2407-2416
[Abstract]
[Full Text]
-
Hobom, U., Brune, W., Messerle, M., Hahn, G., Koszinowski, U. H.
(2000). Fast Screening Procedures for Random Transposon Libraries of Cloned Herpesvirus Genomes: Mutational Analysis of Human Cytomegalovirus Envelope Glycoprotein Genes. J. Virol.
74: 7720-7729
[Abstract]
[Full Text]